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Receptors have fascinated biologists for more than a century and they have fascinated me for the entirety of my own research career. The seven
transmembrane receptors, also known as G protein coupled receptors, represent the largest of the several families of plasma membrane receptors,
comprising more than a thousand genes and regulating virtually all known physiological processes in mammals. Moreover, they represent one of
the commonest targets of currently used drugs. I have spent the entirety of my research career working on these receptors. Here I set down some
personal reflections on the evolution of the field during the past 35 years, hanging the thread of the story on some of the work from my own
laboratory.
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first half of the twentieth century speculated about the existence
of receptors. But it was not until the 1970s that the first
molecular approaches to studying them and to even proving that
they existed were developed. Surprisingly, the intellectual
climate at this time was in fact one of very significant
skepticism as to the actual existence of receptors. For example,
here is a quotation from the mid 1970s from the distinguished
pharmacologist Raymond Ahlquist, who ironically had been
responsible for the development of the concept of alpha and
beta-adrenergic receptors in 1948 using classical, physiological
and pharmacological techniques. He expressed the prevailing
sentiment at the time (1973) which was one of marked
skepticism as to the actual physical existence of such molecules.⁎ Tel.: +1 919 684 2974; fax: +1 919 684 8875.
E-mail address: lefko001@receptor-biol.duke.edu.
0005-2736/$ - see front matter © 2006 Elsevier B.V. All rights reserved.
doi:10.1016/j.bbamem.2006.11.001He wrote: “This would be true if I were so presumptuous as to
believe that α and β receptors really did exist. There are those
that think so and even propose to describe their intimate
structure. To me they are an abstract concept conceived to
explain observed responses of tissues produced by chemicals of
various structure” [1]. So it was against this background of
skepticism that those of us who were interested in the receptor
problem at the time and wished to bring these mythical
receptors to life, began the work. It was immediately clear that it
would be necessary to develop a whole series of new
technologies which did not then exist, and that the first of
these would have to be radioligand binding methods to study
the receptors directly.
For reasons that were both practical and perhaps somewhat
emotional, (I was after all an aspiring young academic
cardiologist), I chose as my models the adrenergic receptors
and particularly the beta-adrenergic receptors. And so in the
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developed radioligand binding approaches for the study of
these receptors. These immediately bore fruit in several areas.
For example, we learned that the receptors were not static
entities but rather were dynamically regulated by all manner of
physiological, pharmacological and pathophysiological situa-
tions. We were also able to discern the existence of novel
receptor subtypes, and to explore novel theories of receptor
action.
For example, we observed that competition curves of
antagonists in radioligand binding experiments gave steep and
uniphasic patterns, whereas agonist competition curves were
shallow and could be resolved into two components. Such
curves were shifted to the right, that is to a single lower
affinity and become steeper in the presence of guanine
nucleotides (Fig. 1). We developed computer based methods
for resolving these various components which were quite
useful for assessing the coupling efficiency of such systems
and which are used to this day. Together with postdoc Andre
deLean, we also developed the so called ternary complex
model which provided early insights into how agonists might
drive the interaction of receptors with a then unknown
additional component, later shown to be the guanine
nucleotide regulatory protein, in order to form the coupled
high affinity state of the receptor (Fig. 1).
But perhaps one of the most important applications of the
ligand binding methods was that they allowed us to begin theFig. 1. High and low affinity states of the β2-adrenergic recedifficult work of receptor solubilization and isolation. At the
time there were three objects of study which were relevant to
receptor biology; the work on the beta2-adrenergic receptor in
my laboratory, that on the nicotinic cholinergic receptor by
laboratories such as that of Changeux and others, and also the
visual pigment rhodopsin. I will return to rhodopsin later but
suffice it to say that at the time, the mid 1970s, no one
imagined that there was any relationship between rhodopsin
and conventional receptors. As an aside let me say that we
were quite envious of our colleagues working on the
cholinergic receptor and also rhodopsin since each of these
constitutes 90% or more of the protein in enriched
membranes derived respectively from the electric organ of
electric fish such as torpedo or from bovine retina. Thus, little
purification was necessary from such membranes. In contrast,
for the beta2 and other adrenergic receptors more than
100,000 fold purification was required after solubilization.
The key to our success was the development of affinity
chromatography matrices for each of the then four known
subtypes of adrenergic receptors. In each case, we coupled
drugs, either alpha or beta-adrenergic antagonists to sepharose
beads. Our first success was the alprenolol-sepharose resin
developed for the βeta receptor by Marc Caron in our group.
By applying solubilized preparations of the various receptors
to such columns coupled to other more conventional
chromatographic matrices we were able, after more than a
decade of difficult and dedicated work, to purify each of theptor and the ternary complex model. Data are from [13].
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geneity (β2, β1 α2, α1).
Each consists of a single polypeptide of about 60,000 Da,
glycoproteins, which bound adrenergic ligands with all the
appropriate specificity and sterospecificity characteristics. I had
imagined that achieving this milestone would finally quell
persisting skepticism about the existence of the receptor
molecules, but this was not so. Skeptics continued to question
whether such isolated molecules could in fact convey to cells
the ability to respond, in this case to adrenergic ligands.
Accordingly, we reconstituted the purified receptors such as
the beta2-adrenergic receptor in phospholipid vesicles and fused
these with cells which, while containing the adenylate cyclase
response system, lacked beta receptors and hence could not
respond to catecholamines. We initially utilized erythrocytes
from Xenopus laevis, which contained prostaglandin but not
beta-adrenergic receptors. When we fused our receptor contain-
ing vesicles with the cells they acquired responsiveness to
adrenaline, thus proving that the isolated ligand binding
proteins were in fact the receptors. Within a year, in
collaboration with Eva Neer and Lutz Birnbaumer, Rick
Cerione in our lab, had reconstituted the pure receptors with
isolated guanine nucleotide regulatory proteins and the
adenylate cyclase catalytic moiety, thus proving that these
three components alone were sufficient to form a neurotrans-
mitter responsive system.Fig. 2. Cloning of the β2 and α2 adrenergic receptors. Residues shaded in blue are ho
consensus sites of regulatory phosphorylation; green, consensus sites for N-linked gWith bonafide validated receptor protein in hand we turned
our attention to the difficult work of cloning the gene and
cDNAs for the receptors. Using microsequencing techniques we
obtained short peptide sequences from purified receptor
proteins, working initially with the beta2-adrenergic receptor.
A postdoc from my lab Cathy Strader who had just finished and
gone on to Merck was instrumental in forming a partnership
between my laboratory and a team at Merck led by Richard
Dixon. Over the next several years we labored together to clone
the receptor, the work in my lab being led by a talented
cardiology fellow named Brian Kobilka. After several years we
succeeded and reported the structure just 20 years ago, in May
of 1986. There were a number of remarkable surprises. The β2-
adrenergic receptor sequence contains all the essential features
that today we view as canonical for the receptor family: seven
membrane spans as predicted from hydropathy plots; sites for
N-linked glycosylation at the amino terminus; sites of
regulatory phosphorylation on the C terminus; and, strikingly,
residues in the membrane spans which were identical to those in
rhodopsin (Fig. 2). The sequence of rhodopsin had been
determined a year or two before independently by two groups
[2,3]. Interestingly this was not by cloning as you might think
but rather by classic Edman degradation since the protein was
available in such large quantities.
Many today are quite surprised to learn just how shocked we
and everyone else in the scientific community was when wemologous with rhodopsin; orange are consensus PKA phosphorylation sites; red,
lycosylation.
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structure of rhodopsin. But it is important to understand the
context. Although by the mid 1980s most of us appreciated the
functional analogies between the rhodopsin/ transducin/cyclic
G phosphodiesterase system and hormone responsive adenylate
cyclases, no one envisioned that the rhodopsin molecule would
actually resemble hormone and neurotransmitter receptors. And
in fact, when the structure of rhodopsin was first obtained, it
was immediately analogized with the only other then known
seven transmembrane spanning protein, bacteriorhodopsin,
[2,3] the light sensitive proton pump from archaebacteria. In
fact, both groups which sequenced rhodopsin came to the same
conclusion, namely that seven membrane spans must be a
signature feature of all light sensitive proteins. Only with the
cloning of the beta2-adrenergic receptor did the idea first
emerge that in fact it was a signature feature of G protein
coupled receptors. This immediately became our hypothesis,
one which my lab quickly supported by cloning first the alpha2-
adrenergic receptor and then over the next several years a total
of 8 adrenergic receptors.
So by 1987 we were quite convinced that all of the then
known G protein coupled receptors would likely be members of
this superfamily of seven transmembrane receptors. Over the
next several years the family grew rapidly as many laboratories
cloned 7TM receptors, almost invariably by homology
techniques such as low stringency screening and then PCR. In
fact, subsequently almost no other 7TM receptor was ever
purified prior to its cloning. Thus, we always felt good about the
very difficult decade or more of work that went into the
purification of the 4 adrenergic receptors which had provided
the first sequences upon which the much larger superfamily
could then be built.
One important example of the consequences of the rapid
growth of the family through the late 1980s and 1990s was the
discovery of so called “orphan receptors”. These of course are
7TM receptors for which the sequence is known but not the
ligand or the function. In fact, today there are still hundreds of
such orphan receptors known from the genome sequence. We
actually discovered the first orphan 7TM receptor immediately
after cloning the beta2 adrenergic receptor when we performed
low stringency southern genomic blots with our beta2 receptor
cDNA. Of the several bands observed, one was most intense.
We assumed that it must represent the beta1-adrenergic receptor
since what else could be so closely related to the beta2? We
cloned it from a size-selected genomic library (the adrenergic
receptor genes and closely related ones are intronless) and to our
delight found that it did in fact encode a 7TM molecule. We
called the clone G21. But to our dismay, when expressed, it did
not bind beta-adrenergic ligands. It thus became the first orphan
GPCR. A year or two later we figured out that G21 was in fact
the first cloned serotonin receptor, the 5HT1A. Thus, it became
the first orphan to be “deorphanized”.
About 5 years later Buck and Axel discovered by far the
largest family of orphans, the olfactory receptors [4]. These
comprise almost half of the superfamily of 7TM receptors and
to this day most of these remain orphans. In the late 1990s
Charles Zucker and others cloned a smaller family of orphantaste receptors, many of which have now been deciphered as
sweet and bitter receptors [5].
With the sequences of several of the receptors in hand our
efforts, and those of a number of other laboratories turned to
trying to understand how the highly conserved 7TM structure of
the receptors mediated the classical functions of ligand binding
and stimulation of biological effects. We utilized two main
approaches, site directed mutagenesis and the construction of
chimeric receptors.
One of my favorite studies from this period involved the
construction of chimeric alpha2 and beta2 adrenergic receptors.
By 1987 we had cloned both of these receptors, based on their
purification, and could see that they were quite homologous.
Both of these adrenergic receptor subtypes bind catecholamines
and related compounds with similar but quite distinct
pharmacologies, but they mediate biochemically and biologi-
cally opposite effects. Thus, the beta2 adrenergic receptors
stimulate adenylate cyclase through Gs, whereas the alpha2-
adrenergic receptors inhibit it through Gi. Brian Kobilka, a
fellow in the lab constructed about a dozen of these chimeras
and I would point out this was in the days before PCR. Fig. 3
depicts six of these, with beta2-adrenergic receptor sequence
shown in red and alpha2 sequence shown in blue. The most
revealing of these chimeric receptors, were #8 and 9 which
contained only a small amount of beta2 sequence and mostly
alpha2 sequence. These chimeras bound ligands with essentially
an alpha 2 specificity but, strikingly, activated adenylate cyclase
as would a beta receptor rather than inhibiting it like an alpha 2.
This immediately told us that the sequences determining
specificity of the G protein coupling must lie within this
relatively limited segment of the molecule. Construction of
additional chimeras and site directed work by us and other
laboratories served to further refine these conclusions. We now
understand that the cytoplasmic domains in closest apposition to
the plasma membrane are generally responsible for determining
coupling to G proteins whereas the membrane spans, external
loops, and N terminus are responsible for ligand binding.
Another interesting and unexpected discovery which flowed
from our mutagenesis and chimeric receptor work was the
serendipitous discovery of constitutively active mutant recep-
tors. Susanna Cotecchia had made a series of mutations in the
third cytoplasmic loop of the alpha 1B adrenergic receptor,
which were expected to lead to loss of function. Instead, several
of these led to constitutive activation of the receptors, that is to
activity in the absence of agonist. Such mutations appear to
abrogate intramolecular interactions which normally constrain
the receptors to an inactive conformation. The discovery of
these constitutively active mutant receptors in turn facilitated
the study and development of “inverse agonists”, agents which
are able to stabilize the inactive conformation of the receptors
and thereby diminish the elevated basal activity of these mutant
receptors. Subsequently, spontaneously occurring mutations
which activate a wide variety of seven transmembrane receptors
have been discovered and have been found to be responsible for
a growing list of human illnesses, including some familial cases
of male precocious puberty (luteinizing hormone receptor) [6]
and functioning thyroid adenomas (thyroid stimulating
Fig. 3. Chimeric α2–β2 adrenergic receptors—adapted from [14].
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also been discovered to encode homologues of constitutively
active 7TM receptors [9].
Despite their remarkable diversity of function many of the
properties of the seven membrane spanning receptors are
conserved. Since the early 1990s, two paradigms have been
central to our understanding of receptor function and regulation.
These two paradigms, activation and desensitization, are based
on the understanding that 3 families of proteins are able to
interact in an almost universal way with 7TM receptors in a
strictly stimulus dependent fashion. These three families are the
heterotrimeric G proteins, the G protein coupled receptor
kinases or GRKs and the beta arrestins.
Interaction of the activated receptors with the G proteins leads
to second messenger generation and classical physiological
responses. Interaction of the activated receptors with GRKs
leads to their phosphorylation, classically on the carboxy
terminal tail. This facilitates the binding of a second class of
proteins called the beta-arrestins, or in the case of rhodopsin
signaling, arrestin which then sterically interdicts further G
protein coupling leading to receptor desensitization.
A brief word about the discovery of the G protein coupled
receptor kinases is in order. I had always been interested in the
pervasive phenomenon of desensitization of biological systems
in the face of persistent stimulation, because it represents
perhaps the most classic example of homeostasis. So whenever
we would develop a new technique for studying the receptors Iwould always want to immediately apply it to the desensitiza-
tion problem. Thus, about 1980 when we first developed
photoaffinity probes for the beta adrenergic receptor we
immediately tried photoaffinity labeling receptors derived
from cells which had been desensitized by prior agonist
exposure and comparing them with receptors from naïve cells.
When we ran SDS gels we could see that the electrophoretic
mobility of the desensitized receptors was retarded compared to
the controls. This suggested that perhaps some covalent
modification of the receptor molecule had occurred. Suspecting
phosphorylation, Jeff Stadel directly tested this by labeling the
cells with 32P and thus we discovered that desensitization of the
beta-adrenergic receptor was associated with its phosphoryla-
tion. These experiments were quite difficult technically because
the only way to isolate the very low abundance receptors (they
were not yet cloned) was to subject each and every sample to
affinity chromatography.
Over the next several years we were able to identify the
kinase responsible for this phosphorylation as a novel protein
kinase which we initially called the beta-adrenergic receptor
kinase (βARK), today generally referred to as GRK2. A
graduate student, Jeff Benovic, was able to purify the kinase
from bovine brain and clone its gene. Contemporaneously with
this work, groups working on the biochemistry of vision had
discovered what seemed like a very analogous enzyme called
rhodopsin kinase which participated in turning off rhodopsin
signaling. We cloned the gene for rhodopsin kinase which
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receptor kinase and thus realized that there was in fact a family
of G protein coupled receptor kinase enzymes.
Today we know that this family consists of 7 enzymes which
we refer to as GRKs 1–7 which regulate virtually all known
7TM receptors. They fall into several subfamilies. GRKs 1 and
7 are found only in the retina, rods and cones respectively. Of
the others, GRKs 2,3,5,6 are ubiquitously expressed. All share a
highly conserved tripartite domain organization with a central
catalytic domain flanked by two regulatory domains.
Our discovery of the beta-arrestins flowed directly from the
work on the GRKs. In the course of purifying βARK or GRK2
from brain we observed that in a reconstituted system that we
were using, the purified enzyme appeared to lose its ability to
desensitize or inactivate the receptors' ability to stimulate G
protein, even as its ability to phosphorylate the receptor
increased. This suggested the possibility that we might be
losing some required cofactor.
Then, as we were scratching our heads about this, Herman
Kuhn and colleagues, in early 1987, reported what was to us the
striking observation that an abundant retinal protein, previously
known as 48K protein or S antigen, worked together with
rhodopsin kinase to deactivate rhodopsin [10]. The protein was
then renamed arrestin. Reasoning that what we were losing
during our βARK preparations might be something similar to
this 48K protein, we obtained some of it from Kuhn and wereFig. 4. New signaling paradigm for 7TM receptors—the β-arrestin/GRK system is
alternate signaling system in its own right.able to show that in our reconstituted system it restored the
desensitizing ability to highly purified βARK preparations. But
still we knew that 48K protein or arrestin was present only in the
retina and hence could not be the molecule we were looking for.
Later that year Shinohara cloned visual arrestin [11].
Reasoning that what we were looking for was a molecule that
might be not only functionally analogous to 48 K protein, but
structurally homologous with it, we obtained Shinohara's
clone and set out to clone related molecules. We succeeded in
cloning a molecule which we termed beta-arrestin, subse-
quently called beta arrestin1 and then a year or two later we
cloned beta-arrestin2.
Now with authentic cloned materials in hand we could set up
parallel reconstitution systems, which included respectively
either rhodopsin kinase-phosphorylated rhodopsin, or βARK
phosphorylated beta receptor. In such systems authentic visual
arrestin was quite potent in inactivating phosphorylated
rhodopsin, whereas the beta-arrestins were quite weak, and
conversely the two beta arrestins were potent in desensitizing
the phosphorylated beta receptor whereas visual arrestin was
very weak. Today we know that there are four arrestins, with
arrestins 1 and 4 being limited to the retina and beta arrestins 1
and 2 (aka arrestins 2 and 3) being ubiquitously expressed. All
of the molecules share about 70% sequence identity and a
highly conserved two domain structure composed almost
exclusively of anti-parallel beta-sheets [12].bifunctional, desensitizing G protein-mediated signaling and also serving as an
754 R.J. Lefkowitz / Biochimica et Biophysica Acta 1768 (2007) 748–755The two forms of beta-arrestin were discovered in the
context of desensitization of the beta receptor where they were
required for full expression of the desensitizing effect of GRK2.
However, quite recently we have discovered that the beta-
arrestins also desensitize receptor signaling by serving as
adaptors which recruit enzymes into complex with the receptors
such as PKA which degrade second messengers.
The second function of the beta-arrestins, appreciated only
over the past 7 or 8 years, is their ability to function as adaptors
linking the receptors to the clathrin mediated endocytosis
machinery. This relies on their ability to bind to clathrin and the
clathrin adaptor AP2, certain small G proteins such as ARF6
and its regulatory proteins, NSF and other elements of the
clathrin coated pit endocytic machinery. We also discovered that
the beta-arrestins bind and are ubiquitinated by the E3 ubiquitin
ligase MDM2. This ubiquitination is absolutely required in
order for it to perform its endocytic functions.
The most recently appreciated role of the beta arrestins,
one which has just begun to come into focus within the past 5
years or so is as a signaling and scaffolding molecule which
mediates a rapidly growing list of signaling pathways. We
first discovered this signaling role in association with the
ability of the beta arrestins to recruit non-receptor tyrosine
kinases such as members of the Src family to the receptors.
But more recently the list of pathways in which the beta
arrestins function has been growing rapidly including, but not
limited to, for example, a variety of MAP kinases including
the ERKs, p38s and JNKs, AKT, PI-3 kinase and a number of
others.
This new information has lead to a new paradigm, one
which emphasizes the bifunctionality of the beta arrestin/GRK
system. Thus, these molecules are on the one hand able to
desensitize G protein mediated signaling while simultaneously
serving as signal transducers in their own right. The in vivo
consequences of this beta arrestin mediated signaling are only
now being elucidated. As shown in Fig. 4, it is already clear
that this signaling leads to various cell survival and anti-
apoptotic effects, mediates some forms of chemotaxis,
mediates a pathway of dopaminergic stimulated behaviors
which is alternative to the classical cAMP pathway, and also
has effects on cardiac contractility. This list will undoubtedly
grow.
Over the past several years the ERK MAP kinases have
served as a very useful model system for gaining understanding
of the mechanisms of this newly delineated beta-arrestin
signaling mechanism. We have utilized the Gq coupled
angiotensin II 1A receptor in particular for studying how this
works. In brief summary, we have found that activation of this
Gq coupled 7TM receptor leads to ERK activation by two quite
distinct parallel pathways. A canonical G-protein, second
messenger pathway leads to ERK activation, with some of the
ERK translocating to the nucleus to regulate transcriptional
programs. In contrast, beta-arrestin mediated activation, which
appears to be mediated exclusively by beta-arrestin2 in this
case, leads to retention of the activated ERK in the cytoplasm,
where presumably it phosphorylates and regulates a distinct set
of cytosolic substrates. Recent data suggest that these substratesregulate such physiological processes as chemotaxis, cytoske-
letal rearrangements and the like. Interestingly beta-arrestin1
not only does not carry the signal from this receptor, but it
appears to act as a physiological dominant negative. Whereas
the G protein pathway is rapid in onset and transient, the beta-
arrestin mediated pathway is slower in onset and much more
persistent.
One of the more exciting ramifications of these newly
discovered β-arrestin-mediated signaling pathways is that they
have been demonstrated for a growing number of 7TM
receptors. Thus, the mechanism appears to be quite general.
Moreover, it is also clear that it is possible to develop ligands
which selectively activate the β-arrestin-mediated pathway
while not activating the G protein pathway. These “biased”
ligands serve as antagonists for G protein-mediated effects of
the receptors even while activating β-arrestin-mediated signal-
ing. Such ligands may represent an entirely novel class of
therapeutic agent. Such “super blockers” would share with
conventional antagonists such as beta blockers or angiotensin
receptor blockers, the ability to competitively antagonize
agonist-activated G protein signaling while simultaneously
adding potentially salutary effects of β-arrestin-mediated
signaling such as, for example, anti-apoptotic effects mediated
through ERK activation, PI3 kinase and AKT.
Clearly, the field of seven transmembrane receptor research
is now expanding exponentially as revealed in the articles which
follow. Hopefully this brief series of personal reflections will
serve to place current work in historical perspective.
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